Xp11.2 TRANSLOCATION RENAL CARCINOMA IN A CHILD
CARCINOMA RENAL CON TRANSLOCACIÓN Xp11.2 EN UNA INFANTE
Gloria Paredes-Guerra¹,², Javier Larios-León²,³, Carol Gonzales-Gonzales³,⁴

ABSTRACT
Translocation renal cell carcinoma (t-RCC) is a subtype of renal cell carcinoma (RCC). This case is about an 11-year-old with pain in right iliac fossa for two weeks. Tumor of 2.2 x 1.9 x 2.8 cm was evidenced in the upper pole of the right kidney, by ultrasound. Then, she underwent to a right radical nephrectomy and regional lymph node dissection, after which CRT subtype Xp 11.2 was diagnosed. Subsequently, first-line treatment with pazopanib and concomitant chemotherapy was initiated. This disease is more frequent between 10 and 15 years. Their prognosis is usually better compared to adults. The multidisciplinary management associated with the availability of first-line medications improves progression-free survival.

Key words: Carcinoma; Renal Cell; Carcinoma; Translocation; Genetic. (source: MeSH NLM)

INTRODUCTION
Advances in molecular technology have led to better typing of renal cancer types and subtypes. As a result, prognostic and predictive factors are now recognized, leading to an increase in cancer-specific survival.

Renal cell carcinomas are very rare neoplasms in children. They are usually found in adults over age 50. Their incidence in children is estimated to be between 1.8% and 6.3%, and its frequency is directly proportional to age¹.

In 2016, the World Health Organization (WHO) classification of genitourinary tumors added, within the subtypes of renal cell carcinomas, MiT family translocation renal cell carcinoma, whose molecular study encompasses Xp11.2 translocation and translocation t⁶(6;11), each with variable clinical features and prognoses²,³.

The management of renal cell carcinomas with translocation is not usually different from other
subtypes of renal cell carcinomas. For this type of neoplasia, the primary treatment is surgery, regardless of the finding of metastasis at the onset of the disease. On the other hand, the use of target medications, such as sunitinib or pazopanib, both tyrosine kinase inhibitors (TKI), have contributed to improved overall survival and disease progression-free survival in these patients. Interdisciplinary management and availability of these drugs are essential to ensure long survival in children carrying translocated renal cell carcinoma(1,2).

The case presented in this report highlights the long progression-free survival of a girl who presented Xp11.2 translocation renal cell carcinoma, determined by fluorescence in situ hybridization (FISH).

**CASE PRESENTATION**

It is presented the case of a 10-year-old girl, who referred to asthenia, pallor, and “stabbing pain” at the level of the right iliac fossa, not irradiated, of two weeks of evolution, for which she went to the clinic emergency in November 2016.

Her personal history is as follows: post-traumatic renal hematoma of 2.2 x1.9x2.8 cm in April 2013.

On physical examination, it is observed a patient with moderate pallor, no signs of active bleeding, with superficial and deep palpation pain at the iliac fossa and right flank level, no evidence of palpable tumors at the abdominal level. The rest of the examination did not contribute.

It is initiated an analgesic treatment with a slight improvement in pain, and it is performed a renal ultrasound, finding, in the upper pole of the right kidney, a solid echogenic image with a hypoechochogenic center with regular edges of 33.6 x 22.7 mm, without internal vascularity.

She is also evaluated by the urologist, who requests that a magnetic resonance of the abdomen be attached to the work plan, where is visualized a nodular image of

<table>
<thead>
<tr>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translocation Xp11.23/17q25.3: Positive for translocation in 83% of the analyzed cells</td>
</tr>
<tr>
<td>Translocation Xp11.23/1q23.1: Negative for translocation in 100% of the analyzed cells</td>
</tr>
</tbody>
</table>
Upon confirmation of the diagnosis of translocation renal cell carcinoma, the patient was typed according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) shown in Table 2. A score of two points was then obtained (considering a time from diagnosis to treatment less than one year and hemoglobin below the normal lower limit). Finally, it was estimated that the patient belonged to the intermediate risk group.

Table 2. MDC classification used to typify the patient after radical nephrectomy.

<table>
<thead>
<tr>
<th>Prognostic factors</th>
<th>Risk groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Time from diagnosis to commencement of treatment less than one year</td>
<td>1. Low-risk group: no prognostic factor</td>
</tr>
<tr>
<td>2) Karnofsky &lt; 80%</td>
<td>2. Intermediate risk group: 0-2 prognostic factors</td>
</tr>
<tr>
<td>3) Hemoglobin below the normal lower limit (normal: 12 g/dl)</td>
<td>3. High-risk group: &gt; 3 prognostic factors</td>
</tr>
<tr>
<td>4) Calcium above the upper normal limit (normal: 8.5-10.2 mg/dl)</td>
<td></td>
</tr>
<tr>
<td>5) Neutrophils above the upper normal limit (normal: 2.0-7.0 x 103/l)</td>
<td></td>
</tr>
<tr>
<td>6) Platelets above the upper normal limit (normal: 150 000-400 000)</td>
<td></td>
</tr>
</tbody>
</table>

The patient starts pazopanib at 400 mg/day for three months. A tomographic control of thorax, abdomen, and pelvis is performed, and it is observed that mediastinal metastatic lesions persist, associating chemotherapy with cisplatin 75 mg/m2 scheme in D1 + gemcitabine 1000 mg/m2 in D1 and D8, every twenty-eight days for a total of six cycles. A partial response is achieved at the level of mediastinal ganglion conglomerate.

Eight months after diagnosis, the patient underwent partial mediastinal node metastasectomy (due to para-esophageal presentation), whose pathological study confirmed metastasis of Xp11.2 translocation renal cell carcinoma.

Due to the persistence of the residual para-esophageal ganglion mass, the start of sunitinib is prescribed, a drug that the parents refuse to administer. Therefore, the patient continues with periodic clinical and imaging controls where the stable persistence of this lesion and a Zubrod score of 0 are evidenced.

Up to the time of publication, the patient has a disease-free survival of approximately eighteen months,
with periodic tomography checks to assess disease progression.

**DISCUSSION**

Renal cell carcinomas are very rare childhood neoplasms, accounting for only 2% to 3% of malignant kidney tumors in children. However, its incidence has been shown to increase with age\(^1\). According to the Japanese Society of Pediatric Surgeons, renal cell carcinomas account for 1.4% of all renal tumors in children under 4 years of age, 15.2% in patients between 5 and 9 years of age, and 52.6% in patients between 10 and 15 years of age, with peak incidence at 9 and 15 years of age\(^2\).

The new category of MiT family translocation renal cell carcinoma has been included into the WHO classification in 2016. The MiT family translocation renal cell carcinoma includes Xp11 translocation renal cell carcinoma and t (6; 11) renal cell carcinoma.

It is essential to establish that t-RCC subtypes Xp11 and t (6; 11) are caused by rearrangements in the genes of the transcription factors TFE3 and TFEB, respectively\(^3,4\).

Determining the exact frequency of t-RCC is a challenge. Some authors such as Kmetec et al.\(^6\) have determined that Xp11 t-RCC represent 20-40% of RCC in children, while the data provided by Komai et al.\(^5\) states that approximately one-third of RCC in children will be t-RCC. The rarity of the tumor causes this difference, such that the clinical-pathological characteristics, prognosis, and treatment have been obtained from retrospective data.

The diagnosis of renal cell carcinomas is usually determined by morphology, while the diagnosis of renal cell carcinomas with translocation requires the verification of rearrangements in the transcription factors TFE3 and TFEB, for which the cytogenetic technique of chromosome marking is generally used, whereby these are hybridized with probes that emit fluorescence (FISH)\(^7,8\).

The case of an 11-year-old girl, with a diagnosis of renal cell carcinoma (clinical stage IV as a result of distant lymph node involvement), was presented. She underwent right-sided radical nephrectomy and regional lymphadenectomy, and subsequently initiated a 400 mg/day pazopanib treatment associated with platinum-based chemotherapy (75 mg/m² cisplatin in D1 + Gemcitabine 1000 mg/m² in D1 and D8) every 28 days for a total of six cycles, allowing the patient to undergo mediastinal nodal resection and maintain a progression-free survival of approximately 18 months.

Sukov et al. published the results of 632 patients with RCC, of which only six were shown to be carriers of rearrangements of TFE3. The researchers established the disease's debut imply nodal involvement associated with a disease of aggressive behavior. Also, the study highlighted a worse progression-free survival (PFS) for those patients who carried the TFE3 rearrangement compared to those who were not carriers\(^9,10\).

The overall survival reported for children with RCC varies according to the following factors: 1) the extent of surgery (radical nephrectomy +/- regional lymph node dissection), 2) clinical stage at debut, 3) availability of first-line drugs in metastatic disease and 4) strict patient follow-up. Indolfi P. et al. performed a retrospective analysis of 41 patients, among children and adolescents, with which they demonstrated that patients with RCC have, on average, an overall survival rate of 63%, with survival rates determined by clinical stage. Besides, they pointed out that between stages I and IV, there is a survival rate of 92.4%, 84.6%, 72.7%, and 13.9%, respectively\(^11\).

Overall survival and progression-free survival in children with Xp11.2 translocation renal cell carcinoma are challenging to determine with accuracy because there is no prospective study in this population group, making it difficult to compare with other subtypes of renal cell carcinoma. It has been established that the prognosis of Xp11.2 translocation renal cell carcinomas in children is better compared to that of adults\(^5,12\).

Al-Daghmin et al. performed a retrospective review of 23 patients with Xp 11.2 translocation renal cell carcinoma, including only two patients younger than 18 years (two girls aged 13 and two years, respectively), and concluded that, after a follow-up of 35 months, the rate of disease-free survival in 3 years was 75%\(^13\). The patient was treated as established by international guidelines and obtained a progression-free survival of approximately 18 months to the present. All this allows us to establish that an adequate initial interdisciplinary management will achieve a long disease-free survival in these patients.

**CONCLUSION**

Multidisciplinary management from the outset associated with the availability of first-line drugs for this type of neoplasms significantly improves progression-free survival in children with translocation renal cell carcinoma.
Authorship Contributions: The authors participated in the genesis of the idea, project design, data collection and interpretation, analysis of results, preparation of the manuscript.

Financing: Self-financed

Interest conflict: The authors declare no conflict of interest.

Received: October 10, 2019
Approved: December 13, 2019

BIBLIOGRAPHIC REFERENCES


